Ventyx Capital Surpluse vs Common Stock Analysis

VTYX Stock

USD 1.73 0.01 0.58%

Ventyx Biosciences financial indicator trend analysis is much more than just breaking down Ventyx Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ventyx Biosciences is a good investment. Please check the relationship between Ventyx Biosciences Capital Surpluse and its Common Stock accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Ventyx Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Ventyx Stock please use our How to Invest in Ventyx Biosciences guide.

Capital Surpluse vs Common Stock

Capital Surpluse vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ventyx Biosciences Capital Surpluse account and Common Stock. At this time, the significance of the direction appears to have totally related.

The correlation between Ventyx Biosciences' Capital Surpluse and Common Stock is 0.99. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Common Stock in the same time period over historical financial statements of Ventyx Biosciences, assuming nothing else is changed. The correlation between historical values of Ventyx Biosciences' Capital Surpluse and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Ventyx Biosciences are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Capital Surpluse i.e., Ventyx Biosciences' Capital Surpluse and Common Stock go up and down completely randomly.

Correlation Coefficient

0.99

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Capital Surpluse

Common Stock

Most indicators from Ventyx Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ventyx Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Ventyx Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Ventyx Stock please use our How to Invest in Ventyx Biosciences guide.Selling General Administrative is likely to rise to about 33.8 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 35.4 M in 2024.

Ventyx Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Other Liab	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Retained Earnings Total Equity	Capital Surpluse
Total Assets		0.08	0.85	0.95	-0.02	0.71	-0.97	-0.81	0.99	0.99	0.82	1.0	0.63	-0.04	0.94	0.97	0.6	1.0	1.0	1.0	-0.44	0.51	0.52	0.75	-0.81	0.78
Short Long Term Debt Total	0.08		0.41	0.32	0.66	0.41	0.06	-0.5	0.21	0.04	0.51	0.05	0.6	0.84	0.25	0.25	0.82	0.02	0.1	0.08	-0.53	0.64	0.63	0.52	-0.31	0.46
Other Current Liab	0.85	0.41		0.92	0.49	0.88	-0.81	-0.99	0.89	0.83	0.74	0.84	0.93	0.1	0.87	0.91	0.71	0.84	0.86	0.86	-0.83	0.88	0.89	0.9	-0.88	0.88
Total Current Liabilities	0.95	0.32	0.92		0.24	0.8	-0.87	-0.91	0.97	0.92	0.85	0.94	0.8	0.08	0.97	1.0	0.73	0.93	0.95	0.95	-0.56	0.7	0.7	0.9	-0.85	0.91
Total Stockholder Equity	-0.02	0.66	0.49	0.24		0.48	0.07	-0.55	0.06	-0.03	0.06	-0.04	0.73	0.22	0.14	0.17	0.38	-0.05	0.01	-0.01	-0.81	0.84	0.83	0.51	-0.29	0.41
Net Tangible Assets	0.71	0.41	0.88	0.8	0.48		-0.58	-0.93	0.76	0.62	0.56	0.69	0.92	0.04	0.86	0.8	0.64	0.69	0.71	0.71	-0.78	0.84	0.84	0.94	-0.98	0.94
Net Debt	-0.97	0.06	-0.81	-0.87	0.07	-0.58		0.73	-0.94	-0.99	-0.75	-0.98	-0.54	0.13	-0.84	-0.9	-0.47	-0.98	-0.97	-0.97	0.41	-0.44	-0.45	-0.61	0.7	-0.64
Retained Earnings	-0.81	-0.5	-0.99	-0.91	-0.55	-0.93	0.73		-0.86	-0.77	-0.73	-0.79	-0.96	-0.16	-0.88	-0.89	-0.76	-0.78	-0.82	-0.81	0.84	-0.91	-0.92	-0.94	0.91	-0.92
Accounts Payable	0.99	0.21	0.89	0.97	0.06	0.76	-0.94	-0.86		0.97	0.87	0.99	0.7	0.07	0.96	0.99	0.7	0.98	0.99	0.99	-0.49	0.58	0.59	0.81	-0.85	0.84
Cash	0.99	0.04	0.83	0.92	-0.03	0.62	-0.99	-0.77	0.97		0.82	0.99	0.59	-0.04	0.88	0.94	0.56	0.99	0.99	0.99	-0.42	0.48	0.49	0.67	-0.73	0.7
Long Term Debt	0.82	0.51	0.74	0.85	0.06	0.56	-0.75	-0.73	0.87	0.82		0.82	0.59	0.52	0.79	0.84	0.9	0.8	0.83	0.83	-0.38	0.49	0.5	0.68	-0.65	0.7
Cash And Short Term Investments	1.0	0.05	0.84	0.94	-0.04	0.69	-0.98	-0.79	0.99	0.99	0.82		0.61	-0.05	0.93	0.96	0.58	1.0	1.0	1.0	-0.42	0.49	0.5	0.72	-0.8	0.76
Common Stock Shares Outstanding	0.63	0.6	0.93	0.8	0.73	0.92	-0.54	-0.96	0.7	0.59	0.59	0.61		0.18	0.77	0.77	0.72	0.61	0.65	0.64	-0.9	0.98	0.98	0.94	-0.84	0.9
Non Current Liabilities Total	-0.04	0.84	0.1	0.08	0.22	0.04	0.13	-0.16	0.07	-0.04	0.52	-0.05	0.18		0.01	0.03	0.73	-0.08	-0.03	-0.04	-0.17	0.2	0.2	0.12	-0.02	0.09
Other Current Assets	0.94	0.25	0.87	0.97	0.14	0.86	-0.84	-0.88	0.96	0.88	0.79	0.93	0.77	0.01		0.98	0.68	0.93	0.94	0.94	-0.5	0.63	0.64	0.91	-0.92	0.94
Other Stockholder Equity	0.97	0.25	0.91	1.0	0.17	0.8	-0.9	-0.89	0.99	0.94	0.84	0.96	0.77	0.03	0.98		0.69	0.96	0.98	0.97	-0.53	0.65	0.66	0.88	-0.86	0.9
Total Liab	0.6	0.82	0.71	0.73	0.38	0.64	-0.47	-0.76	0.7	0.56	0.9	0.58	0.72	0.73	0.68	0.69		0.55	0.61	0.6	-0.56	0.67	0.67	0.74	-0.65	0.73
Net Invested Capital	1.0	0.02	0.84	0.93	-0.05	0.69	-0.98	-0.78	0.98	0.99	0.8	1.0	0.61	-0.08	0.93	0.96	0.55		1.0	1.0	-0.41	0.48	0.49	0.72	-0.8	0.76
Total Current Assets	1.0	0.1	0.86	0.95	0.01	0.71	-0.97	-0.82	0.99	0.99	0.83	1.0	0.65	-0.03	0.94	0.98	0.61	1.0		1.0	-0.45	0.53	0.54	0.76	-0.81	0.8
Net Working Capital	1.0	0.08	0.86	0.95	-0.01	0.71	-0.97	-0.81	0.99	0.99	0.83	1.0	0.64	-0.04	0.94	0.97	0.6	1.0	1.0		-0.44	0.52	0.53	0.75	-0.81	0.79
Other Liab	-0.44	-0.53	-0.83	-0.56	-0.81	-0.78	0.41	0.84	-0.49	-0.42	-0.38	-0.42	-0.9	-0.17	-0.5	-0.53	-0.56	-0.41	-0.45	-0.44		-0.95	-0.95	-0.71	0.7	-0.64
Non Currrent Assets Other	0.51	0.64	0.88	0.7	0.84	0.84	-0.44	-0.91	0.58	0.48	0.49	0.49	0.98	0.2	0.63	0.65	0.67	0.48	0.53	0.52	-0.95		1.0	0.85	-0.74	0.79
Net Receivables	0.52	0.63	0.89	0.7	0.83	0.84	-0.45	-0.92	0.59	0.49	0.5	0.5	0.98	0.2	0.64	0.66	0.67	0.49	0.54	0.53	-0.95	1.0		0.86	-0.75	0.8
Common Stock Total Equity	0.75	0.52	0.9	0.9	0.51	0.94	-0.61	-0.94	0.81	0.67	0.68	0.72	0.94	0.12	0.91	0.88	0.74	0.72	0.76	0.75	-0.71	0.85	0.86		-0.91	0.99
Retained Earnings Total Equity	-0.81	-0.31	-0.88	-0.85	-0.29	-0.98	0.7	0.91	-0.85	-0.73	-0.65	-0.8	-0.84	-0.02	-0.92	-0.86	-0.65	-0.8	-0.81	-0.81	0.7	-0.74	-0.75	-0.91		-0.93
Capital Surpluse	0.78	0.46	0.88	0.91	0.41	0.94	-0.64	-0.92	0.84	0.7	0.7	0.76	0.9	0.09	0.94	0.9	0.73	0.76	0.8	0.79	-0.64	0.79	0.8	0.99	-0.93

Click cells to compare fundamentals

Ventyx Biosciences Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Ventyx Stock Analysis

When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ventyx Capital Surpluse vs Common Stock Analysis

Capital Surpluse vs Common Stock

Capital Surpluse vs Common Stock Correlation Analysis

Correlation Coefficient

Capital Surpluse

Common Stock

Ventyx Biosciences fundamental ratios Correlations

Ventyx Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Ventyx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Other Stockholder Equity	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Cash And Short Term Investments

Cash	- 0.99	Net Debt
Retained Earnings	- 0.99	Other Current Liab
Net Invested Capital	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Retained Earnings Total Equity	- 0.98	Net Tangible Assets
Net Working Capital	- 0.97	Net Debt